research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
== Biocontrol properties == Some P. fluorescens strains (CHA0 or Pf-5, for example) present biocontrol properties, protecting the roots of some plant species against parasitic fungi such as Fusarium or the oomycete Pythium, as well as some phytophagous nematodes, and insect pests. It is not clear exactly how the plant growth-promoting properties of P. fluorescens are achieved; theories include:
Galanin-like peptide (GALP) is a neuropeptide present in humans and other mammals. It is a 60-amino acid polypeptide produced in the arcuate nucleus of the hypothalamus and the posterior pituitary gland. It is involved in the regulation of appetite and may also have other roles such as in inflammation, sex behavior, and stress. Findings additionally suggest that GALP could play a function in energy metabolism due to its ability to maintain continual activation of the sympathetic nervous system (SNS) via thermogenesis, which refers to the production of heat within living organisms. In addition, the administration of GALP directly into the brain leads to a reduction in the secretion of thyroid-stimulating hormone (TSH), which indicates the involvement of GALP in the neuroendocrine regulation of the hypothalamic-pituitary-thyroid (HPT) axis, and further adding to the evidence of the role of GALP in energy homeostasis.
==== Implantation ==== The first cells of the embryo to undergo EMT and form mesenchyme are the extra-embryonic cells of the trophectoderm. These migrate from the body of the blastocyst into the endometrial layer of the uterus in order to contribute to the formation of the anchored placenta.
Sources: en.wikipedia.org
== Safety == Inhalation of n-hexane at 5000 ppm for 10 minutes produces marked vertigo; 2500-1000 ppm for 12 hours produces drowsiness, fatigue, loss of appetite, and paresthesia in the distal extremities; 2500–5000 ppm produces muscle weakness, cold pulsation in the extremities, blurred vision, headache, and anorexia. Chronic occupational exposure to elevated levels of n-hexane has been demonstrated to be associated with peripheral neuropathy in auto mechanics in the US, and neurotoxicity in workers in printing presses, and shoe and furniture factories in Asia, Europe, and North America. The US National Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit (REL) for hexane isomers (not n-hexane) of 100 ppm (350 mg/m3 (0.15 gr/cu ft)) over an 8-hour workday. However, for n-hexane, the current NIOSH REL is 50 ppm (180 mg/m3 (0.079 gr/cu ft)) over an 8-hour workday. This limit was proposed as a permissible exposure limit (PEL) by the Occupational Safety and Health Administration in 1989; however, this PEL was overruled in US courts in 1992. The current n-hexane PEL in the US is 500 ppm (1,800 mg/m3 (0.79 gr/cu ft)). Hexane and other volatile hydrocarbons (petroleum ether) present an aspiration risk. n-Hexane is sometimes used as a denaturant for alcohol, and as a cleaning agent in the textile, furniture, and leather industries. It is slowly being replaced with other solvents. Like gasoline, hexane is highly volatile and is an explosion risk.
== Factors in hemostasis and fibrinolysis == Stimulators of coagulation: All factors in the coagulation cascade. While the endothelium does produce some factor VIII, the majority of factor VIII is produced in the liver. Inhibitors of coagulation: Inactivate an enormous variety of proteinases α2-macroglobulin α1-antitrypsin Antithrombin III Protein S Protein C Fibrinolysis: Breakdown of fibrin clots Plasminogen Inhibitors of fibrinolysis α2-antiplasmin Complement components C1-9, complement component 3 (C3)
=== EC 1.20.4 Acting on phosphorus or arsenic in donors, with disulfide as acceptor === EC 1.20.4.1: arsenate reductase (glutaredoxin) EC 1.20.4.2: methylarsonate reductase EC 1.20.4.3: mycoredoxin EC 1.20.4.4: arsenate reductase (thioredoxin)
=== Late 19th century === Following the Napoleonic Wars, the British Empire became the world's leading power, controlling one-quarter of the world's population and one-third of the land area. It enforced a Pax Britannica, encouraged trade, and battled rampant piracy. Slavery was greatly reduced around the world. Following a successful slave revolt in Haiti, Britain forced the Barbary pirates to halt their practice of kidnapping and enslaving Europeans, passed the Slavery Abolition Act 1833 which banned slavery throughout its domain, and charged its navy with ending the global slave trade. Slavery was then abolished in Russia in 1861, by the Emancipation Proclamation in the United States in 1863, and in Brazil in 1888. (see Abolitionism). Following the abolition of the slave trade, and propelled by economic exploitation, the Scramble for Africa was initiated formally at the Berlin West Africa Conference in 1884–1885. All the major European powers laid claim to the areas of Africa where they could exhibit a sphere of influence over the area. These claims did not have to have any substantial land holdings or treaties to be legitimate. The French gained major ground in West Africa, the British in East Africa, and the Portuguese and Spanish at various points throughout the continent, while Leopold II of Belgium was able to retain his personal fiefdom, Congo. Electricity, steel, and petroleum fuelled a Second Industrial Revolution which enabled Germany, Japan, and the United States to become great powers that raced to create empires of their own.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.